Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
BCCA - Vancouver, Vancouver, British Columbia, Canada
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
MD Anderson in The Woodlands, Conroe, Texas, United States
M D Anderson Cancer Center, Houston, Texas, United States
MD Anderson West Houston, Houston, Texas, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University Hospital Antwerpen, Antwerpen, Belgium
University Hospital Hamburg, Hamburg, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.